Granules India Ltd vs Laurus Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Apr 04, 2026

Key Highlights

The Latest Trading Price of Granules India Ltd is ₹ 614 as of 02 Apr 15:30 . The P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 yearsThe P/E Ratio of Laurus Labs Ltd changed from 19.8 on March 2021 to 92.4 on March 2025 . This represents a CAGR of 36.08% over 5 years The Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 yearsThe Market Cap of Laurus Labs Ltd changed from ₹ 19427 crore on March 2021 to ₹ 33099 crore on March 2025 . This represents a CAGR of 11.24% over 5 years The revenue of Granules India Ltd for the Dec '25 is ₹ 1384 crore as compare to the Sep '25 revenue of ₹ 1295 crore. This represent the growth of 6.83% The revenue of Laurus Labs Ltd for the Dec '25 is ₹ 1784 crore as compare to the Sep '25 revenue of ₹ 1680 crore. This represent the growth of 6.17% The ebitda of Granules India Ltd for the Dec '25 is ₹ 304.46 crore as compare to the Sep '25 ebitda of ₹ 277.08 crore. This represent the growth of 9.88% The ebitda of Laurus Labs Ltd for the Dec '25 is ₹ 485.97 crore as compare to the Sep '25 ebitda of ₹ 430.22 crore. This represent the growth of 12.96% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 150.21 crore over 7 quarters. This represents a CAGR of 6.45% The net profit of Laurus Labs Ltd changed from ₹ 12.21 crore to ₹ 253.11 crore over 7 quarters. This represents a CAGR of 465.38% The Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 yearsThe Dividend Payout of Laurus Labs Ltd changed from 11.22 % on March 2021 to 17.01 % on March 2025 . This represents a CAGR of 8.68% over 5 years .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

FAQs for the comparison of Granules India Ltd and Laurus Labs Ltd

Which company has a larger market capitalization, Granules India Ltd or Laurus Labs Ltd?

Market cap of Granules India Ltd is 14,899 Cr while Market cap of Laurus Labs Ltd is 56,371 Cr

What are the key factors driving the stock performance of Granules India Ltd and Laurus Labs Ltd?

The stock performance of Granules India Ltd and Laurus Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Laurus Labs Ltd?

As of April 4, 2026, the Granules India Ltd stock price is INR ₹614.0. On the other hand, Laurus Labs Ltd stock price is INR ₹1044.2.

How do dividend payouts of Granules India Ltd and Laurus Labs Ltd compare?

To compare the dividend payouts of Granules India Ltd and Laurus Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.